Cytokinetics’ target raised to $20 from $14 at Cantor Fitzgerald

Cytokinetics (NASDAQ:CYTK)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, The Fly reports. They currently have a $20.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $14.00.

Cytokinetics’ (CYTK) “Overweight” Rating Reaffirmed at Cantor Fitzgerald